October 22, 2009 5:03 PM
- Text
Pfizer's Viagra Shows Signs of Flagging: Sales Down 6%
(MoneyWatch) Pfizer's Viagra recorded a 6 percent sales decline, to $466 million worldwide. It wasn't just foreign currency headwinds: The decline was 14 percent in international sales and 1 percent in the U.S. Until now, Viagra has been an almost unstoppable growth machine for Pfizer. The company regularly put the price up -- sometimes twice a year -- and netted more dollars per quarter as a result.
So the decline begs a question: Has Viagra completely tapped out its market, or has it lost market share to either Eli Lilly's Cialis (up 16 percent to $149.4 million in Q2) or Bayer's Levitra (anemic growth at best)?
Two factors complicate the issue. The first is that although Viagra is down, Revatio -- Pfizer's pulmonary arterial hypertension drug which is made of the same thing as Viagra -- saw sales rise 18 percent to $111 million. Second, Viagra goes generic in the next few years and Chinese manufacturers are already flooding the market with illegal generic versions.
I recently asked Pfizer what their plans were for the generic Viagra challenge: Keep marketing the "real thing" or license it? The company demurred, and gave this statement:
So the decline begs a question: Has Viagra completely tapped out its market, or has it lost market share to either Eli Lilly's Cialis (up 16 percent to $149.4 million in Q2) or Bayer's Levitra (anemic growth at best)?Two factors complicate the issue. The first is that although Viagra is down, Revatio -- Pfizer's pulmonary arterial hypertension drug which is made of the same thing as Viagra -- saw sales rise 18 percent to $111 million. Second, Viagra goes generic in the next few years and Chinese manufacturers are already flooding the market with illegal generic versions.
I recently asked Pfizer what their plans were for the generic Viagra challenge: Keep marketing the "real thing" or license it? The company demurred, and gave this statement:
"We will not comment on future plans for Viagra. Pfizer benefits from having options when our medicines go off-patent. We currently have a thriving generics business, and also will have a consumer health business at such time as we satisfy the closing conditions and acquire Wyeth. As with all our medicines, we continually explore options for patients to have access to them."It's tempting to dissect that statement for a subtext. Why did Pfizer mention its generics business in the same breath as its consumer segment? Could it be that Pfizer is hoping to persude the FDA to give it some kind of behind-the-counter status -- such as in the U.K. -- where patients can buy it without prescription as long as the pharmacist assures him/herself that the patient isn't on nitrates for blood pressure (mixing Viagra with nitrates can be fatal).
- Related:
- Price of Viagra Has Risen 108% Since Launch; 100 Pills Now Cost $1,400
- Pfizer Rep Claims Zoloft Touted for Failed Cheerleaders; Viagra for Women
- Pfizer Rep Alleges Viagra Promoted With Unapproved Materials: "Get Those Things Cleaned Up!"
- Cialis Goes Up Against Viagra in Hypertension Add-On War
- Lilly Q2: It's Downhill From Here, Say Analysts; Cialis Gains on Viagra
Latest Now in MoneyWatch
- Kodak to stop making digital cameras, frames
- Market cap, schmarket cap, Apple still gets no respect
- Philip Morris Int'l income up nearly 8 percent
- Survey: Small biz plans big hires in 2012
- Freddie Mac: Mortgages inch higher but stay low
- Will the European debt crisis sink Obama's re-election?
- Banks in $25B deal to settle foreclosure abuses
- Joe Coffee: Scaling up without selling your soul
- Greek agreement accomplishes nothing
- 401K plans: New rules make costs clearer
- Are women leaders selling themselves short?
- Ask the Experts: New 401(k) rules
- Mortgage lenders strike a deal
- $25B foreclosure-abuse settlement reached
- Wholesale inventories rose 1 percent in December
- States, Feds to announce new mortgage settlement
- Management changes at Ford
Latest CBS News Headlines
on Facebook
on CBS News
- Summary Box: Greek cuts may be too little
- Warner Music 1Q revenue flat; digital sales jump
- Summary Box: Widening gap between young and old
- Report says Apple to unveil new iPad in March
on Facebook
- Adele opens up about vocal cord surgery
- Mo. teen gets life in prison for murder of 9-year-old girl
- "American Idol": Jim Carrey's daughter out, and then disaster
on CBS News






